Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma – novel and emerging therapies

References

• ZelenetzADAbramsonJSAdvaniRHNCCN Clinical Practice Guidelines in Oncology: non-Hodgkin’s lymphomasJ Natl Compr Canc Netw20108328833420202462
   PubMed Web of Science ®Google Scholar
• JaffeESHarrisNLSteinHVardimanJWWorld Health OrganizationClassification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues33rd edLyonIARC2001
   Google Scholar
• CoiffierBThieblemontCVan Den NesteELong-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’AdulteBlood2010116122040204520548096
   PubMed Web of Science ®Google Scholar
• GlennieMJFrenchRRCraggMSTaylorRPMechanisms of killing by anti-CD20 monoclonal antibodiesMol Immunol200744163823383717768100
   PubMed Web of Science ®Google Scholar
• DavisTAGrillo-LópezAJWhiteCARituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: safety and efficacy of re-treatmentJ Clin Oncol200018173135314310963642
   PubMed Web of Science ®Google Scholar
• MartínACondeEArnanMR-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO studyHaematologica200893121829183618945747
   PubMed Web of Science ®Google Scholar
• HagbergHGisselbrechtCRandomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL studyAnn Oncol200617Suppl 4iv31iv3216702182
   PubMed Web of Science ®Google Scholar
• RezvaniARMaloneyDGRituximab resistanceBest Pract Res Clin Haematol201124220321621658619
   PubMed Web of Science ®Google Scholar
• ShimizuRKikuchiJWadaTOzawaKKanoYFurukawaYHDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cellsLeukemia201024101760176820686505
   PubMed Web of Science ®Google Scholar
• MoskowitzCHBertinoJRGlassmanJRIfosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin’s lymphomaJ Clin Oncol199917123776378510577849
   PubMed Web of Science ®Google Scholar
• KewalramaniTZelenetzADNimerSDRituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphomaBlood2004103103684368814739217
   PubMed Web of Science ®Google Scholar
• RaiKRPetersonBLAppelbaumFRFludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemiaN Engl J Med2000343241750175711114313
   PubMed Web of Science ®Google Scholar
• MolicaSProgress in the treatment of chronic lymphocytic leukemia: results of the German CLL8 trialExpert Rev Anticancer Ther20111191333134021929307
   PubMed Web of Science ®Google Scholar
• CatovskyDRichardsSMatutesEAssessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trialLancet2007370958323023917658394
   PubMed Web of Science ®Google Scholar
• DohnerHStilgenbauerSBennerAGenomic aberrations and survival in chronic lymphocytic leukemiaN Engl J Med2000343261910191611136261
   PubMed Web of Science ®Google Scholar
• van OersMHKlasaRMarcusRERituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trialBlood2006108103295330116873669
   PubMed Web of Science ®Google Scholar
• HagemeisterFBTreatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescueCancer Chemother Pharmacol200249Suppl 1S13S2012042984
   PubMed Web of Science ®Google Scholar
• PhilipTGuglielmiCHagenbeekAAutologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphomaN Engl J Med199533323154015457477169
   PubMed Web of Science ®Google Scholar
• PeniketAJRuiz de ElviraMCTaghipourGAn EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantationBone Marrow Transplant200331866767812692607
   PubMed Web of Science ®Google Scholar
• SwannJBSmythMJImmune surveillance of tumorsJ Clin Invest200711751137114617476343
   PubMed Web of Science ®Google Scholar
• AppelbaumFRHematopoietic cell transplantation for non-Hodgkin’s lymphoma: yesterday, today, and tomorrowJ Clin Oncol200826182927292918565876
   PubMed Web of Science ®Google Scholar
• BrownJRThe treatment of relapsed refractory chronic lymphocytic leukemiaHematology Am Soc Hematol Educ Program2011201111011822160021
   PubMed Web of Science ®Google Scholar
• MayesSBrownNIllidgeTMNew antibody drug treatments for lymphomaExpert Opin Biol Ther201111562364021395497
   PubMed Web of Science ®Google Scholar
• CangSMukhiNWangKLiuDNovel CD20 monoclonal antibodies for lymphoma therapyJ Hematol Oncol201256423057966
   PubMed Web of Science ®Google Scholar
• ChesonBDOfatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignanciesJ Clin Oncol201028213525353020458041
   PubMed Web of Science ®Google Scholar
• TeelingJLFrenchRRCraggMSCharacterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomasBlood200410461793180015172969
   PubMed Web of Science ®Google Scholar
• GuptaIVJewellRCOfatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignanciesAnn NY Acad Sci20121263435622830942
   PubMed Web of Science ®Google Scholar
• CoiffierBLepretreSPedersenLMSafety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1–2 studyBlood200811131094110018003886
   PubMed Web of Science ®Google Scholar
• WierdaWGKippsTJMayerJOfatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemiaJ Clin Oncol201028101749175520194866
   PubMed Web of Science ®Google Scholar
• WierdaWGKippsTJDurigJChemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemiaBlood2011117246450645821498674
   PubMed Web of Science ®Google Scholar
• CzuczmanMSFayadLDelwailVOfatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter studyBlood2012119163698370422389254
   PubMed Web of Science ®Google Scholar
• CzuczmanMSHessGGadebergOVChemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphomaBr J Haematol2012157443844522409295
   PubMed Web of Science ®Google Scholar
• MorschhauserFMarltonPVitoloUResults of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphomaAnn Oncol20102191870187620157180
   PubMed Web of Science ®Google Scholar
• GoldenbergDMMorschhauserFWegenerWAVeltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospectsLeuk Lymphoma201051574775520214444
   PubMed Web of Science ®Google Scholar
• MorschhauserFLeonardJPFayadLHumanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin’s lymphoma: phase I/II resultsJ Clin Oncol200927203346335319451441
   PubMed Web of Science ®Google Scholar
• TuXLaValleeTLechleiderRCD22 as a target for cancer therapyJ Exp Ther Oncol20119324124822070056
   PubMedGoogle Scholar
• LeonardJPLinkBKImmunotherapy of non-Hodgkin’s lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab)Semin Oncol2002291 Suppl 2818611842393
   PubMed Web of Science ®Google Scholar
• StraussSJMorschhauserFRechJMulticenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin’s lymphomaJ Clin Oncol200624243880388616864854
   PubMed Web of Science ®Google Scholar
• GottliebABKangSLindenKGEvaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasisClin Immunol20041111283715093549
   PubMed Web of Science ®Google Scholar
• Vyth-DreeseFABootHDellemijnTALocalization in situ of costimulatory molecules and cytokines in B-cell non-Hodgkin’s lymphomaImmunology19989445805869767448
   PubMed Web of Science ®Google Scholar
• CzuczmanMSThallAWitzigTEPhase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphomaJ Clin Oncol200523194390439815994148
   PubMed Web of Science ®Google Scholar
• CzuczmanMSLeonardJPJungSPhase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsivenessAnn Oncol20122392356236222357442
   PubMed Web of Science ®Google Scholar
• IshidaTUtsunomiyaAIidaSClinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcomeClin Cancer Res2003910 Pt 13625363414506150
   PubMed Web of Science ®Google Scholar
• YamamotoKUtsunomiyaATobinaiKPhase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphomaJ Clin Oncol20102891591159820177026
   PubMed Web of Science ®Google Scholar
• IshidaTJohTUikeNDefucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II studyJ Clin Oncol201230883784222312108
   PubMed Web of Science ®Google Scholar
• AdvaniACoiffierBCzuczmanMSSafety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin’s lymphoma: results of a phase I studyJ Clin Oncol201028122085209320308665
   PubMed Web of Science ®Google Scholar
• FayadLPatelHVerhoefGSafety and clinical activity of the anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) in combination with rituximab in follicular lymphoma or diffuse large B-cell lymphoma: preliminary report of a phase 1/2 studyASH Annu Meet Abstr200811211266
   Google Scholar
• ClodiKYounesAReed-Sternberg cells and the TNF family of receptors/ligandsLeuk Lymphoma1997273–41952059402319
   PubMed Web of Science ®Google Scholar
• Forero-TorresALeonardJPYounesAA phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphomaBr J Haematol2009146217117919466965
   PubMed Web of Science ®Google Scholar
• BlumKAJungSHJohnsonJLSerious pulmonary toxicity in patients with Hodgkin’s lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcgammaRIIIa-158 V/F polymorphismAnn Oncol201021112246225420423913
   PubMed Web of Science ®Google Scholar
• Garnock-JonesKPBrentuximab vedotin: a review of its use in patients with Hodgkin lymphoma and systemic anaplastic large cell lymphoma following previous treatment failureDrugs201373437138123494187
   PubMed Web of Science ®Google Scholar
• ProBAdvaniRBricePBrentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II studyJ Clin Oncol201230182190219622614995
   PubMed Web of Science ®Google Scholar
• ViardotAGoebelerMNopponeyRBlinatumomab monotherapy shows efficacy in patients with relapsed diffuse large B cell lymphomaASH Annu Meet Abstr20111881637
   Google Scholar
• KaminskiMSZelenetzADPressOWPivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomasJ Clin Oncol200119193918392811579112
   PubMed Web of Science ®Google Scholar
• FisherRIKaminskiMSWahlRLTositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin’s lymphomasJ Clin Oncol200523307565757316186600
   PubMed Web of Science ®Google Scholar
• HorningSJYounesAJainVEfficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximabJ Clin Oncol200523471271915613695
   PubMed Web of Science ®Google Scholar
• WitzigTEFlinnIWGordonLITreatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphomaJ Clin Oncol200220153262326912149300
   PubMed Web of Science ®Google Scholar
• GordonLIMolinaAWitzigTDurable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 studyBlood2004103124429443115016644
   PubMed Web of Science ®Google Scholar
• PressOWUngerJMRimszaLMPhase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016J Clin Oncol201331331432023233710
   PubMed Web of Science ®Google Scholar
• WitzigTEWhiteCAGordonLISafety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin’s lymphomaJ Clin Oncol20032171263127012663713
   PubMed Web of Science ®Google Scholar
• GoldsmithSJRadioimmunotherapy of lymphoma: Bexxar and ZevalinSemin Nucl Med201040212213520113680
   PubMed Web of Science ®Google Scholar
• BennettJMKaminskiMSLeonardJPAssessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomabBlood2005105124576458215731177
   PubMed Web of Science ®Google Scholar
• CzuczmanMSEmmanouilidesCDarifMTreatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapyJ Clin Oncol200725274285429217709799
   PubMed Web of Science ®Google Scholar
• RodonJDienstmannRSerraVTaberneroJDevelopment of PI3K inhibitors: lessons learned from early clinical trialsNat Rev Clin Oncol201310314315323400000
   PubMed Web of Science ®Google Scholar
• SchatzJHTargeting the PI3K/AKT/mTOR pathway in non-Hodgkin’s lymphoma: results, biology, and development strategiesCurr Oncol Rep201113539840621755275
   PubMed Web of Science ®Google Scholar
• EngelmanJATargeting PI3K signalling in cancer: opportunities, challenges and limitationsNat Rev Cancer20099855056219629070
   PubMed Web of Science ®Google Scholar
• HermanSEGordonALWagnerAJPhosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signalsBlood2010116122078208820522708
   PubMed Web of Science ®Google Scholar
• KahlBByrdJCFlinnIWClinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110delta, in patients with relapsed or refractory non-Hodgkin lymphomaASH Ann Meet Abstr20101661777
   Google Scholar
• FurmanRRByrdJCBrownJRCAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110delta, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemiaASH Ann Meet Abstr201011655
   Google Scholar
• CoutreSELeonardJPFurmanRRCombinations of the selective phosphatidylinositol 3-kinase-delta (PI3 Kdelta) inhibitor GS-1101 (CAL-101) with rituximab and/or bendamustine are tolerable and highly active in patients with relapsed or refractory chronic lymphocytic leukemia (CLL): results from a phase I studyASH Ann Meet Abstr2012120191
   Google Scholar
• FurmanRRBarrientosJCSharmanJPA phase I/II study of the selective phosphatidylinositol 3-kinase-delta (PI3 Kdelta) inhibitor, GS-1101 (CAL-101), with ofatumumab in patients with previously treated chronic lymphocytic leukemia (CLL)J Clin Oncol201230Suppl6518
   Google Scholar
• RobakPRobakTA targeted therapy for protein and lipid kinases in chronic lymphocytic leukemiaCurr Med Chem201219315294531822830347
   PubMed Web of Science ®Google Scholar
• RichardsonPGEngCKolesarJHideshimaTAndersonKCPerifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activityExpert Opin Drug Metab Toxicol20128562363322512706
   PubMed Web of Science ®Google Scholar
• GuidettiAVivianiSMarchianoADual targeted therapy with the AKT inhibitor perifosine and the multikinase inhibitor sorafenib in patients with relapsed/refractory lymphomas: final results of a phase II trialASH Annu Meet Abstr20121203679
   Google Scholar
• ConleyMEDobbsAKFarmerDMPrimary B cell immunodeficiencies: comparisons and contrastsAnnu Rev Immunol20092719922719302039
   PubMed Web of Science ®Google Scholar
• DavisRENgoVNLenzGChronic active B-cell-receptor signalling in diffuse large B-cell lymphomaNature20104637277889220054396
   PubMed Web of Science ®Google Scholar
• AdvaniRHBuggyJJSharmanJPBruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignanciesJ Clin Oncol2013311889423045577
   PubMed Web of Science ®Google Scholar
• O’BrienSBurgerJABlumKAThe Bruton’s tyrosine kinase (BTK) inhibitor PCI-32765 induces durable responses in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): follow-up of a phase Ib/II studyASH Annu Meet Abstr2011118983
   Google Scholar
• ByrdJCFurmanRRCoutreSEThe Bruton’s tyrosine kinase (BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients (pts): Interim results of a phase Ib/II studyJ Clin Oncol201230Suppl6507
   Google Scholar
• O’BrienSMBarrientosJCFlinnIWCombination of the Bruton’s tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)/rituximab (R) (BR) in patients (Pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): interim results of a phase Ib/II studyJ Clin Oncol201230Suppl6515
   Google Scholar
• JaglowskiSMJonesJAFlynnJMA phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseasesJ Clin Oncol201230Suppl6508
   Google Scholar
• BrownJRIbrutinib (PCI-32765), the first BTK (Bruton’s tyrosine kinase) inhibitor in clinical trialsCurr Hematol Malig Rep2013811623296407
   PubMed Web of Science ®Google Scholar
• BrownJRSharmanJPHarbWAPhase Ib trial of AVL-292, a covalent inhibitor of Bruton’s tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL)J Clin Oncol201230Suppl8032
   Google Scholar
• KahanBDCamardoJSRapamycin: clinical results and future opportunitiesTransplantation20017271181119311602840
   PubMed Web of Science ®Google Scholar
• DudkinLDillingMBCheshirePJBiochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibitionClin Cancer Res2001761758176411410517
   PubMed Web of Science ®Google Scholar
• HippSRingshausenIOelsnerMBognerCPeschelCDeckerTInhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cellsHaematologica200590101433143416219581
   PubMed Web of Science ®Google Scholar
• HessGHerbrechtRRomagueraJPhase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphomaJ Clin Oncol200927233822382919581539
   PubMed Web of Science ®Google Scholar
• SmithSMvan BesienKKarrisonTTemsirolimus has activity in non-mantle cell non-Hodgkin’s lymphoma subtypes: the University of Chicago phase II consortiumJ Clin Oncol201028314740474620837940
   PubMed Web of Science ®Google Scholar
• WitzigTEReederCBLaPlantBRA phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphomaLeukemia201125234134721135857
   PubMed Web of Science ®Google Scholar
• ZentCSLaPlantBRJohnstonPBThe treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulationCancer201011692201220720166206
   PubMed Web of Science ®Google Scholar
• Macias-PerezIMFlinnIWB-cell receptor pathobiology and targeting in NHLCurr Oncol Rep201214541141822865093
   PubMed Web of Science ®Google Scholar
• FriedbergJWSharmanJSweetenhamJInhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemiaBlood2010115132578258519965662
   PubMed Web of Science ®Google Scholar
• AstraZenecaStudy to learn if 200 mg test drug (fostamatinib) helps people with large B-cell lymphoma, a type of blood cancerBethesda, MDUS National Library of Medicine2011 [updated June 4, 2013]. Available from: http://clinicaltrials.gov/show/NCT01499303. NLM identifier: NCT01499303Accessed June 17, 2013
   Google Scholar
• AstraZenecaA randomised double blind phase II trial to evaluate the efficacy of two doses of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) NLM identifier: NCT01499303
   Google Scholar
• GascoyneRDAdomatSAKrajewskiSPrognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin’s lymphomaBlood19979012442519207459
   PubMed Web of Science ®Google Scholar
• StolzCHessGHahnelPSTargeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosisBlood200811283312332118689543
   PubMed Web of Science ®Google Scholar
• WobserMVoigtHEggertAOBcl-2 expression in rituximab refractory cutaneous B-cell lymphomaBr J Cancer200796101540154317473827
   PubMed Web of Science ®Google Scholar
• WatersJSWebbACunninghamDPhase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin’s lymphomaJ Clin Oncol20001891812182310784621
   PubMed Web of Science ®Google Scholar
• ProBLeberBSmithMPhase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphomaBr J Haematol2008143335536018764869
   PubMed Web of Science ®Google Scholar
• O’BrienSMooreJOBoydTE5-Year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersenJ Clin Oncol200927315208521219738118
   PubMed Web of Science ®Google Scholar
• WilsonWHO’ConnorOACzuczmanMSNavitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activityLancet Oncol201011121149115921094089
   PubMed Web of Science ®Google Scholar
• KahlBRobertsAWSeymourJFNavitoclax (ABT-263) plus rituximab: interim results of a phase 1 study in patients with CD20-positive lymphoid malignanciesASH Annu Meet Abstr20101163943
   Google Scholar
• TangJYanHZhuangSHistone deacetylases as targets for treatment of multiple diseasesClin Sci (Lond)20131241165166223414309
   PubMed Web of Science ®Google Scholar
• KirschbaumMFrankelPPopplewellLPhase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin’s lymphoma and mantle cell lymphomaJ Clin Oncol20112991198120321300924
   PubMed Web of Science ®Google Scholar
• BuddeLEZhangMMShustovARA phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphomaBr J Haematol2013161218319123356514
   PubMed Web of Science ®Google Scholar
• GisselbrechtCGlassBMounierNSalvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab eraJ Clin Oncol201028274184419020660832
   PubMed Web of Science ®Google Scholar
• PiekarzRLFryeRPrinceHMPhase 2 trial of romidepsin in patients with peripheral T-cell lymphomaBlood2011117225827583421355097
   PubMed Web of Science ®Google Scholar
• SwainSMWhaleyFSEwerMSCongestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trialsCancer200397112869287912767102
   PubMed Web of Science ®Google Scholar
• SalvatorelliEMennaPPazOGThe novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patientsJ Pharmacol Exp Ther2013344246747823192654
   PubMed Web of Science ®Google Scholar
• MinottiGMennaPSalvatorelliECairoGGianniLAnthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicityPharmacol Rev200456218522915169927
   PubMed Web of Science ®Google Scholar
• CavallettiECrippaLMainardiPPixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantroneInvest New Drugs200725318719517285358
   PubMed Web of Science ®Google Scholar
• BorchmannPSchnellRKnippertzRPhase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin’s lymphomaAnn Oncol200112566166711432625
   PubMed Web of Science ®Google Scholar
• PettengellRCoiffierBNarayananGPixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trialLancet Oncol201213769670622652183
   PubMed Web of Science ®Google Scholar
• PaoluzziLO’ConnorOAMechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomasBioDrugs2006201132316573348
   PubMed Web of Science ®Google Scholar
• FriedbergJWVoseJMKellyJLThe combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphomaBlood2011117102807281221239695
   PubMed Web of Science ®Google Scholar
• RibragVGisselbrechtCHaiounCEfficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA)Cancer2009115194540454619593797
   PubMed Web of Science ®Google Scholar
• de VosSGoyADakhilSRMulticenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphomaJ Clin Oncol200927305023503019770386
   PubMed Web of Science ®Google Scholar
• AgathocleousARohatinerARuleSWeekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemiaBr J Haematol2010151434635320880120
   PubMed Web of Science ®Google Scholar
• FisherRIBernsteinSHKahlBSMulticenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphomaJ Clin Oncol200624304867487417001068
   PubMed Web of Science ®Google Scholar
• ZinzaniPLPellegriniCMerlaEBortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective studyHematol Oncol Epub10292012
   Web of Science ®Google Scholar
• CoiffierBOsmanovEAHongXBortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trialLancet Oncol201112877378421724462
   PubMed Web of Science ®Google Scholar
• ChiappellaAVitoloULenalidomide in diffuse large B-cell lymphomasAdv Hematol2012201249834222792112
   PubMedGoogle Scholar
• WiernikPHLossosISTuscanoJMLenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphomaJ Clin Oncol200826304952495718606983
   PubMed Web of Science ®Google Scholar
• WitzigTEVoseJMZinzaniPLAn international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphomaAnn Oncol20112271622162721228334
   PubMed Web of Science ®Google Scholar
• ZinzaniPLPellegriniCGandolfiLCombination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trialClin Lymphoma Myeloma Leuk201111646246621859554
   PubMed Web of Science ®Google Scholar
• WangMFayadLWagner-BartakNLenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trialLancet Oncol201213771672322677155
   PubMed Web of Science ®Google Scholar
• ChiappellaAFranceschettiSCastellinoACarellaAMRituximab-CHOP21 plus lenalidomide (LR-CHOP21) is effective and feasible in elderly untreated diffuse large B-cell lymphoma (DLBCL): results of phase II REAL07 study of the Fondazione Italiana Linfomi (FIL)Presented at: 54th ASH Annual Meeting and ExpositionDecember 8–11, 2012Atlanta, GA, USA
   Google Scholar
• MicallefINMaurerMJWisemanGAEpratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphomaBlood2011118154053406121673350
   PubMed Web of Science ®Google Scholar
• CoiffierBProBPrinceHMResults from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapyJ Clin Oncol201230663163622271479
   PubMed Web of Science ®Google Scholar
• ZinzaniPLKhuagevaNKWangHBortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naive or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trialJ Hematol Oncol201256723088650
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN)NCCN Clinical Practice Guidelines in OncologyNon-Hodgkin’s Lymphomas Version 1.2013 Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
   Google Scholar